

CAS ONLINE PRINTOUT

=> d his

(FILE 'HOME' ENTERED AT 10:52:23 ON 01 SEP 2007)

FILE 'REGISTRY' ENTERED AT 10:52:35 ON 01 SEP 2007

L1 STRUCTURE UPLOADED  
L2 2 S L1  
L3 123 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:53:37 ON 01 SEP 2007

L4 70 S L3  
L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:02:08 ON 01 SEP 2007

L6 20 SEARCH L1 CSS SUB=L3 FULL

FILE 'CAPLUS' ENTERED AT 11:02:42 ON 01 SEP 2007

L7 13 S L6

=> d bib abs hitstr 1-13

L7 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1349256 CAPLUS

DN 146:197744

TI Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

AU Lin, Linus S.; Lanza, Thomas J., Jr.; Jewell, James E.; Liu, Ping; Shah, Shrenik K.; Qi, Hongbo; Tong, Xinchun; Wang, Junying; Xu, Suoyu S.; Fong, Tung M.; Shen, Chun-Pyn; Lao, Julie; Xiao, Jing Chen; Shearman, Lauren P.; Stribling, D. Sloan; Rosko, Kimberly; Strack, Alison; Marsh, Donald J.; Feng, Yue; Kumar, Sanjeev; Samuel, Koppa; Yin, Wenji; Van der Ploeg, Lex H. T.; Goulet, Mark T.; Hagmann, William K.

CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA


SO Journal of Medicinal Chemistry (2006), 49(26), 7584-7587  
CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

GI



AB The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts

CAS ONLINE PRINTOUT

led to the identification of compound 48 (I) for development as a clin. candidate for the treatment of obesity.


IT 605679-99-0P 605680-28-2P 922501-65-3P  
922501-66-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity)


RN 605679-99-0 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester  
(CA INDEX NAME)




RN 605680-28-2 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
(CA INDEX NAME)




RN 922501-65-3 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-fluorophenyl)-, methyl ester  
(CA INDEX NAME)



RN 922501-66-4 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(2-fluorophenyl)-, methyl ester  
(CA INDEX NAME)




## CAS ONLINE PRINTOUT

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2005:42938 CAPLUS  
DN 142:48182  
TI Preparation of aralkyl amines as cannabinoid-1 receptor modulators  
IN Shah, Shreshik K.; Truong, Quang T.; Qi, Hongbo; Hagmann, William K.  
PA Merck & Co., Inc., USA  
SO PCT Int. Appl., 137 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005044785	A1	20050519	WO 2004-US35846	20041027
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004287849	A1	20050519	AU 2004-287849	20041027
	CA 2543882	A1	20050519	CA 2004-2543882	20041027
	EP 1682494	A1	20060726	EP 2004-796666	20041027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1871208	A	20061129	CN 2004-80031512	20041027
	JP 2007510647	T	20070426	JP 2006-538259	20041027
	IN 2006DN01892	A	20070615	IN 2006-DN1892	20060407
	US 2007088058	A1	20070419	US 2006-576381	20060419
PRAI	US 2003-515705P	P	20031030		
	WO 2004-US35846	W	20041027		
OS	MARPAT 142:481820				
GI					



I


## CAS OF LINE PRINTOUT

AB Aralkyl amines ((Ar1X)C(R1)(R2)CH(R2)N(R3)(R4)(R5)Ar3 (I); variables defined below; e.g. 2 diastereomers of 3-[(1-(4-chlorobenzyl)-2-(S\*)-[2-hydroxy-2-methyl-1-(R\*)-phenylpropyl]amino)propyl]benzonitrile (shown as II)) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compds. of the present invention are useful as centrally acting drugs in the treatment or psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compds. are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. For I: R1 = H, C1-4alkyl, (un)substituted with 1-3 Re, halogen, and -ORd; R2 = H, C1-4alkyl, and aryl, wherein each alkyl and aryl moiety is (un)substituted with 1-3 Re; R3 = H, and C1-4alkyl, (un)substituted with 1-3 Re; R4 = H, C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C1-10alkyloxycarbonyl-, C3-10cycloalkyl, aryl, C1-6alkyl-, and heteroaryl-C1-6-alkyl-, wherein each alkyl, alkenyl, and alkynyl moiety is (un)substituted with 1-4 Ra and each aryl, heteroaryl, and cycloalkyl moiety is (un)substituted with 1-3 Rb and oxo; R5 = H, and C1-4alkyl, (un)substituted with 1-3 Re. Ar1 = C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-10cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl, wherein each alkyl, alkenyl, and alkynyl moiety is (un)substituted with 1-3 Ra, each aryl and heteroaryl moiety is (un)substituted with 1-4 Rb and each cycloalkyl and cycloheteroalkyl moiety is (un)substituted with 1-4 Rb and oxo; Ar2 = -ORd, -CO2Rd, C3-10cycloalkyl, cycloheteroalkyl, aryl, and heteroaryl, wherein each cycloalkyl, cycloheteroalkyl moiety is (un)substituted with 1-4 Rb and oxo and each aryl and heteroaryl moiety is (un)substituted with 1-4 Rb; Ar3 = cycloalkyl, aryl, and heteroaryl, wherein each cycloalkyl, aryl and heteroaryl moiety is (un)substituted with 1-4 Rb; X = a bond, C1-4alkyl, O, S, and -NRC-, provided that when X is O, S, or -NRC-, then R1 is H or C1-4alkyl and Ar2 is not -ORd; addnl. details are given in the claims. Although the methods of preparation are not claimed, >100 example preps. and/or characterization data for I are included. For example, II was prepared from [3-(4-chlorophenyl)-2-(S\*)-(3-cyanophenyl)-1-(S\*)-methylpropyl]amine, 2-hydroxy-2-methylpropiophenone and NaHB(OAc)3 in dichloroethane. Compds. I were tested in a CB1 binding assay and found to have an IC50 value of  $\leq 2 \mu\text{M}$ . Selective CB1 antagonist/inverse agonist compds. have IC50s 100-fold greater in the CB2 binding assay than in the CB1 assay, and generally have IC50s  $> 1 \mu\text{M}$  in the CB2 binding assay. CB1 antagonist/inverse agonist compds. I generally have EC50s of  $< 1 \mu\text{M}$  in a CB1 functional assay and selective CB1 antagonist/inverse agonists generally have EC50s  $> 1 \mu\text{M}$  in the CB2 functional assay.


IT 605679-99-0P, Methyl 3-(4-Chlorophenyl)-2-(3-fluorophenyl)propionate 605680-28-2P, Methyl 2,3-Bis(4-chlorophenyl)propionate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of aralkyl amines as cannabinoid-1 receptor modulators)

RN 605679-99-0 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester  
(CA INDEX NAME)



RN 605680-28-2 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro-α-(4-chlorophenyl)-, methyl ester  
 (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2005:281753 CAPLUS  
 DN 142:355050  
 TI Preparation of aryl sulfonamides as cannabinoid CB1 receptor antagonists  
 and/or inverse agonists.  
 IN Armstrong, Helen M.; Chang, Linda L.; Guthikonda, Ravindra N.; Hagmann,  
 William K.; Lin, Linus S.; Shah, Shrenik K.  
 PA Merck & Co., Inc.us, USA  
 SO PCT Int. Appl., 122 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005027837	A2	20050331	WO 2004-US30122	20040914
	WO 2005027837	A3	20061005		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
	NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
	TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
	AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
	EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
	SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
	SN, TD, TG				
	AU 2004273865	A1	20050331	AU 2004-273865	20040914
	CA 2538291	A1	20050331	CA 2004-2538291	20040914
	EP 1663113	A2	20060607	EP 2004-784093	20040914
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1956949	A	20070502	CN 2004-80026822	20040914
	JP 2007521322	T	20070802	JP 2006-526984	20040914
	IN 2006DN00879	A	20070810	IN 2006-DN879	20060220

## CAS ONLINE PRINTOUT

US 2007-15914 A1 20070510 US 2006-571842 20060315  
 PRAI US 2003-104377P P 20030918  
 WO 2004-0530122 W 20040914  
 OS CASREACT 142:355050; MARPAT 142:355050  
 AB R1R2R6CCR3R7NR4SO2R5 [I; R1 = (substituted) alkyl, cycloalkyl(alkyl), cycloheteroalkyl(alkyl), (hetero)aryl(alkyl), etc.; R2 = (substituted) alkyl, cycloalkyl(alkyl), cycloheteroalkyl(alkyl), (hetero)aryl(alkyl); R3, R7 = H, (substituted) alkyl, cycloalkyl(alkyl), (hetero)aryl(alkyl), cycloheteroalkyl(alkyl); R4 = H, (substituted) alkyl; R5 = (substituted) alkyl, alkenyl, alkynyl, cycloheteroalkyl(alkyl), cycloalkyl(alkyl), (hetero)aryl(alkyl), etc.; R6 = H, OH, alkyl, halo, cyano; with provisos], were prepared Thus, 2-amino-3,4-bis(4-chlorophenyl)butane hydrochloride, diisopropylethylamine, and tert-butylsulfinyl chloride were stirred together in CH<sub>2</sub>Cl<sub>2</sub> for 2 h to give N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2-propanesulfinimide. This was stirred with m-ClC<sub>6</sub>H<sub>4</sub>C(O)OOH in CH<sub>2</sub>Cl<sub>2</sub> to give N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-methyl-2-propanesulfonimide. I generally have EC<sub>50</sub> values of <1 μM in a CB<sub>1</sub> functional assay.  
 IT 605679-99-0P, Methyl 3-(4-chlorophenyl)-2-(3-fluorophenyl)propionate 605680-28-2P, Methyl 2,3-bis(4-chlorophenyl)propionate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aryl sulfonamides as cannabinoid CB<sub>1</sub> receptor antagonists and/or inverse agonists)  
 RN 605679-99-0 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro-α-(3-fluorophenyl)-, methyl ester (CA INDEX NAME)



RN 605680-28-2 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro-α-(4-chlorophenyl)-, methyl ester (CA INDEX NAME)




L7 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:837028 CAPLUS  
 DN 139:337785  
 TI Preparation of substituted arylamides as cannabinoid-1 receptor antagonists and/or inverse agonists for use as psychotropic drugs  
 IN Hagmann, William K.; Lin, Linus S.; Shah, Shrenik K.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 191 pp.  
 CODEN: PIXXD2

## CAS ONLINE PRINTOUT

DT Patent  
LA English  
FAN.CN

PI	W	NO.	KIND	DATE	APPLICATION NO.	DATE
PI	W	2003087037	A1	20031023	WO 2003-US9800	20030401
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA	2480856	A1	20031023	CA 2003-2480856	20030401
	AU	2003226149	A1	20031027	AU 2003-226149	20030401
	EP	494997	A1	20050112	EP 2003-746565	20030401
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US	2005154202	A1	20050714	US 2003-509277	20030401
	JP	2005527586	T	20050915	JP 2003-583993	20030401
PRAI	US	2002-370553P	P	20020405		
	WO	2003-US9800	W	20030401		
OS	MARPAT 139:337785					
GI						



AB Title compds. I [wherein R1 = (un)substituted alkyl, (hetero)cycloalkyl, or (hetero)aryl; R2 = (un)substituted (hetero)cycloalkyl, (hetero)aryl, ORd, NRcRd, or CO2Rd; R3 = H or (un)substituted alkyl; R6 = H, halo, CN, NRcRd, or (un)substituted alkyl, alkenyl, or alkynyl; Ar = (un)substituted (hetero)aryl; Rc and Rd = independently H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)cycloalkyl(alkyl), or (hetero)aryl(alkyl); or NRcRd = (un)substituted heterocyclyl; or two ORc groups together with the atoms to which they are attached = (un)substituted heterocyclyl; with provisos; and pharmaceutically acceptable salts thereof] were prepared by conventional and automated synthesis methods as antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor (no data). For example, 2,3-bis(4-chlorophenyl)-1-methylpropylamine•HCl was acylated with 2-benzofuran-2-carboxylic acid in the presence of PyBop and TEA in CH2Cl2 to give the desired amide II. I and their pharmaceutical compns. are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuroinflammatory disorders, including multiple sclerosis and Guillain-Barre syndrome, and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents,

ONLINE PRINTOUT


and head trauma, anxiety disorder, sleep movement disorders, and schizophrenia pharmaceutical compns. are useful for disorders, the treatment of obesity; or treatment of asthma, constipation, ch and cirrhosis of the liver (no data).

TI 605679-99-0P, Methyl 3-(4-Chlorophenyl- (3-  
fluorophenyl)propionate 605680-28-2P, 2,3-Bis(4-chlorophenyl)propionate yl  
RL: RCT (Reactant); SPN (Synthetic pre tion); PREP (Preparation); RACT  
(Reactant or reagent) ed arylamides as CB1 receptor  
(intermediate; preparation of subst use as psychotropic drugs)  
antagonists and/or inverse agonists

RN 605679-99-0 CAPLUS


CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester

(CA INDEX NAME)



RN 605680-28-2 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
(CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:836767 CAPLUS

DN 139:337784

TI Preparation of substituted bicyclic arylamide cannabinoid-1 receptor  
antagonists and/or inverse agonists for use as psychotropic drugs

IN Castonguay, Laurie A.; Hagmann, William K.; Lin, Linus S.; Shah, Shrenik  
K.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 189 pp.  
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003086288	A2	20031023	WO 2003-US10740	20030408
	WO 2003086288	A3	20040805		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,



## CAS ONLINE PRINTOUT


GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, K, LR, LS,  
 LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, Z, OM, PH,  
 PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, R, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, K, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 CA 2481313 A1 20031023 CA 2003-2481313 20030408  
 AU 2003223510 A1 20031027 AU 2003-223510 20030408  
 EP 1499306 A2 20050126 EP 2003-719642 20030408  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005534621 T 20051117 JP 2003-583315 20030408  
 US 2005203112 A1 20050915 US 2004-509584 20040929  
 PRAI US 2002-372234P P 20020412  
 WO 2003-US10740 W 20030408  
 OS MARPAT 139:337784  
 GI




AB Title compds. I [wherein R1 = (un)substituted alkyl (hetero)cycloalkyl, or (hetero)aryl; R2 = (un)substituted (hetero)cycloalkyl, (hetero)aryl, ORd, NRcRd, or CO2Rd; R3 = (un)substituted (cyclo)alkyl, alkenyl, or alkynyl; R4 = H, ORc, CO2Rc, OCORc, OCO2Rc, OCONRdRe, NRdRe, NHCO2Rc, NRcSO2Rc, SO1-2Rc, or (un)substituted alkyl, alkenyl, alkynyl, or (hetero)aryl; R6 = H, halo, CN, NRcRd, or (un)substituted alkyl, alkenyl, or alkynyl; A = 3- to 8-membered (un)substituted monocyclic saturated ring incorporating the same C to which R4 is attached and optionally containing 1-2 heteroatoms, and to which a (hetero)aryl ring is fused, wherein said bicyclic ring is optionally fused to another (hetero)aryl ring to form a tricyclic ring; Rc and Rd = independently H or (un)substituted alkyl, alkenyl, alkynyl, (hetero)cycloalkyl(alkyl), or (hetero)aryl(alkyl); or NRcRd = (un)substituted heterocyclyl; or two ORc groups together with the atoms to which they are attached = (un)substituted heterocyclyl; Re = H, (cyclo)alkyl, alkenyl, alkynyl, (hetero)cycloalkyl(alkyl), or (hetero)aryl(alkyl); and pharmaceutically acceptable salts thereof] were prepared by conventional and automated synthesis methods as antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor (no data).

For example, 1,2,3,4-tetrahydro-2-naphthoic acid was converted to the acyl chloride using oxalyl chloride and DMF in CH<sub>2</sub>Cl<sub>2</sub>. Acylation of 2,3-bis(4-chlorophenyl)-1-methylpropylamine•HCl with the naphthoic chloride in the presence of diisopropylethylamine in CH<sub>2</sub>Cl<sub>2</sub> provided a diastereomeric mixture of amides II, which were separated on a silica gel column. I and their pharmaceutical compns. are useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuroinflammatory disorders, including multiple sclerosis and Guillain-Barre syndrome, and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia (no data). In addition, I and their pharmaceutical compns. are useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver (no data). Novel compds. of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor.

IT 605679-99-0P, Methyl 3-(4-Chlorophenyl)-2-(3-fluorophenyl)propionate 605680-28-2P, Methyl 2,3-Bis(4-chlorophenyl)propionate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate; preparation of substituted bicyclic arylamide CB1 receptor antagonists and/or inverse agonists for use as psychotropic drugs)  
 RN 605679-99-0 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester  
 (CA INDEX NAME)



RN 605680-28-2 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
 (CA INDEX NAME)



L7 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:796415 CAPLUS  
 DN 139:307605  
 TI Preparation of spirocyclic carboxamides as cannabinoid receptor modulators  
 IN Hagmann, William K.; Lin, Linus S.; Shah, Shrenik K.; Goulet, Mark T.; Jewell, James P.  
 PA Merck & Co., Inc., USA  
 SO PCT Int. Appl., 224 pp.

## CAS ONLINE PRINTOUT


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003082190	A2	20031009	WO 2003-US8722	20030321
	WO 2003082190	A3	20040219		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2479618	A1	20031009	CA 2003-2479618	20030321
	AU 2003215024	A1	20031013	AU 2003-215024	20030321
	EP 1490043	A2	20041229	EP 2003-711667	20030321
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	JP 2005528366	T	20050922	JP 2003-579733	20030321
	US 2005239828	A1	20051027	US 2004-507864	20040916
PRAI	US 2002-367655P	P	20020326		
	WO 2003-US8722	W	20030321		
OS	MARPAT 139:307605				
GI					



I


AB R1CH2CR2R3CHR4NHCOA [R1 = (un)substituted alkyl, cycloalkyl, heterocyclic, aryl; R2 = (un)substituted cycloalkyl, heterocyclic, aryl, OH, NH2, CO2H; R3 = H, (un)substituted alkyl, alkenyl, alkynyl, OH, NH2, halogen, CN; R4 = H, (un)substituted alkyl; A = (un)substituted 3-8-membered carbocyclic ring] were prepared and are antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor, useful as psychotropic drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compds. are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as, the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Thus, PhCH2CO2Me was treated with 4-ClC6H4CH2Br to give 4-ClC6H4CH2CHPhCO2Me which was hydrolyzed to the acid, converted to 4-ClC6H4CH2CHPhCONMeOMe, and treated with MeMgBr to give 4-ClC6H4CH2CHPhCOMe. This ketone was reduced to the alc., converted to the mesylate and then to the azide which was reduced to

## CAS ONLINE PRINTOUT


4-ClC6H4CH2CHPhCHMeNH<sub>2</sub>·HCl. Treatment of this amine with phenylcyclopentanecarboxylic acid gave the amide I.

IT 605679-99-0P 605680-28-2P  
 RL: RCT (Reactant); SYN (Synthetic preparation); PREP (Preparation);  
 (Reactant or reagent)  
 (preparation of spirocyclic carboxamides as cannabinoid receptor modulators)

RN 605679-99-0 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester  
 (CA INDEX NAME)



RN 605680-28-2 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
 (CA INDEX NAME)





L7 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:757469 CAPLUS  
 DN 139:276471  
 TI Preparation of substituted amides as antagonists and/or inverse agonists of the cannabinoid-1 receptor for therapy  
 IN Hagmann, William K.; Lin, Linus S.; Shah, Shrenik K.; Guthikonda, Ravindra N.; Qi, Hongbo; Chang, Linda L.; Liu, Ping; Armstrong, Helen M.; Jewell, James P.; Lanza, Thomas J., Jr.  
 PA Merck & Co., Inc., USA; et al.  
 SO PCT Int. Appl., 381 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003077847	A2	20030925	WO 2003-US7320	20030307
	WO 2003077847	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

## CAS ONLINE PRINTOUT


CA 2478183	A1	20030925	CA 2003-	8183	2	0307
AU 2003218068	A1	20030929	AU 2003-	068	2	0307
AU 2003218068	B2	20070215				
EP 1496838	A2	20050119	EP 2003-	051	2	0307
R: AT, BE,						
IE, SI,						
DE, DK, ES, FR, GB, GR, IT,						
LV, FI, RO, MK, CY, AL, TR,						
PT,						
JP 2005519958	T	20050707	JP 2003-	901	2	0307
JP 3813152	B2	20060823				
NZ 534757	A	20060728	NZ 2003-	757	2	0307
US 2004058820	A1	20040325	US 2003-	265	2	0312
US 6972295	B2	20051206				
US 2005234061	A1	20051020	US 2005-	076	2	0419
JP 2006257090	A	20060928	JP 2006-	912	2	0407
AU 2007201276	A1	20070419	AU 2007-	276	2	0323
PRAI US 2002-363597P	P	20020312				
US 2002-428351P	P	20021122				
AU 2003-218068	A3	20030307				
JP 2003-575901	A3	20030307				
WO 2003-US7320	W	20030307				
US 2003-387265	A3	20030312				
OS MARPAT 139:27647						
GI						




AB Novel compds. of the structural formula I (e.g. N-[2,3-bis(4-chlorophenyl)-1-methylpropyl]-2-(pyrazol-1-yl)acetamide trifluoroacetate (base shown as II with relative stereochem.); variables defined below) are antagonists and/or inverse agonists of the cannabinoid-1 (CB1) receptor (no data) and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compds. of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compds. are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver. Although the methods of preparation are not claimed, more than 120 example

preps. of intermediates and >480 example preps./characterization data for a library of I are included. For I: R1 = C1-10-alkyl, C3-10cycloalkyl, C3-10-cycloalkyl-C1-4-alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-4alkyl, aryl, aryl-C1-4-alkyl, heteroaryl, heteroaryl-C1-4-alkyl, -ORd, -NRcRd, -NRcC(O)Rd, -CO2Rd, and -C(O)NRcRd. R2 = C1-10alkyl, C3-10cycloalkyl-C1-4alkyl, cycloheteroalkyl, cycloheteroalkyl-C1-4alkyl; aryl, aryl-C1-4alkyl, aryloxy, arylthio, heteroaryl, and heteroaryl-C1-4alkyl; R3 = H, and C1-4alkyl; R4 = H, and C1-4alkyl; R5 = C1-10alkyl, C2-10alkenyl, C3-10-cycloalkyl-C1-4alkyl, cycloheteroalkyl-C1-4-alkyl, aryl-C1-4-alkyl, diaryl-C1-4alkyl, aryl-C1-4alkenyl, heteroaryl-C1-4alkyl, -ORd, and -NRcRd; addnl. details including provisos are given in the claims.

IT 605679-99-0P, Methyl 3-(4-Chlorophenyl)-2-(3-fluorophenyl)propionate 605680-28-2P, Methyl 2,3-Bis(4-chlorophenyl)propionate  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted amides as antagonists and/or inverse agonists of cannabinoid-1 receptor for therapy)  
 RN 605679-99-0 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(3-fluorophenyl)-, methyl ester  
 (CA INDEX NAME)



RN 605680-28-2 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
 (CA INDEX NAME)




L7 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2003:262921 CAPLUS  
 DN 139:85155  
 TI Intermolecular C-H activation at benzylic positions: synthesis of (+)-imperanene and (-)- $\alpha$ -conidendrin  
 AU Davies, Huw M. L.; Jin, Qihui  
 CS Department of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260-3000, USA  
 SO Tetrahedron: Asymmetry (2003), 14(7), 941-949  
 CODEN: TASYE3; ISSN: 0957-4166  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 OS CASREACT 139:85155  
 AB An efficient C-H activation of primary benzylic positions by means of

CAS ONLINE PRINTOUT


rhodium carbenoid induced C-H insertions is described. This key step  
used in concise synthesis of (+)-imperanene and (-)- $\alpha$ -conidendrin.  
IT 553642-18-5P 553642-21-0  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of (+)-imperanene and (-)- $\alpha$ -conidendrin in a benzene  
derivative and an aryl diazoacetate via a rhodium carbenoid induced  
insertion)  
RN 553642-18-5 CAPLUS  
CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-methoxy-, methyl ester,  
( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 553642-21-0 CAPLUS  
CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-methyl-, methyl ester,  
( $\alpha$ R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2002:301227 CAPLUS  
DN 137:32995  
TI Catalytic Asymmetric Benzylic C-H Activation by Means of Carbenoid-Induced  
C-H Insertions  
AU Davies, Huw M. L.; Jin, Qihui; Ren, Pingda; Kovalevsky, Andrey Yu.  
CS Department of Chemistry, University at Buffalo State University of New  
York, Buffalo, NY, 14260-3000, USA  
SO Journal of Organic Chemistry (2002), 67(12), 4165-4169  
CODEN: JOCEAH; ISSN: 0022-3263  
PB American Chemical Society  
DT Journal  
LA English  
OS CASREACT 137:32995  
AB Tetrakis[N-(4-dodecylphenylsulfonyl)](S)-prolinate]dirhodium  
[Rh<sub>2</sub>(S-DOSP)<sub>4</sub>]-catalyzed decomposition of Me aryldiazoacetates in the presence  
of substituted ethylbenzenes results in benzylic C-H activation by a  
Rh-carbenoid-induced C-H insertion. A Hammett study showed that pos.  
charge buildup occurred on the benzylic C in the transition state of the

CAS ONLINE PRINTOUT

C-H activation step. C-H activation of toluene and isopropylbenzene is possible, but a competing double cyclopropanation occurs with these substrates. The C-H activation is highly regioselective and enantioselective, and in certain cases, moderate diastereoselectivity is also possible.


IT 436144-76-2P 436144-79-5P 436144-84-2P  
436144-86-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(catalytic asym. benzylic C-H activation by means of carbenoid-induced C-H insertions)

RN 436144-76-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-methoxy- $\beta$ -methyl-, methyl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 436144-79-5 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)- $\beta$ ,4-dimethyl-, methyl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 436144-84-2 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-methoxy- $\beta$ -methyl-, methyl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 436144-86-4 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)- $\beta$ ,4-dimethyl-, methyl



CAS ONLINE PRINTOUT

ester, ( $\alpha$ R, $\beta$ S)- (9CI) CA INDEX NAME)

Absolute stereochemistry.



IT 436144-77-3P 436144-81-9P 436144-85-3P


436144-88-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(catalytic asym. benzylic C-H activation by means of carbenoid induced C-H insertions)

RN 436144-77-3 CAPLUS

CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-ethyl- $\beta$ -methyl-, methyl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 436144-81-9 CAPLUS

CN Benzenepropanoic acid, 4-bromo- $\alpha$ -(4-bromophenyl)- $\beta$ -methyl-, methyl ester, ( $\alpha$ R, $\beta$ R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 436144-85-3 CAPLUS


CN Benzenepropanoic acid,  $\alpha$ -(4-bromophenyl)-4-ethyl- $\beta$ -methyl-, methyl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 436144-88-6 CAPLUS  
 CN Benzenepropanoic acid, 4-bromo- $\alpha$ -(4-bromophenyl)- $\beta$ -methyl-,  
 methyl ester, ( $\alpha$ R, $\beta$ S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1996:248888 CAPLUS  
 DN 125:10861  
 TI Arthropodicidal benzopyranopyrazole- and indenooxadiazine-derived anilides  
 IN Barnette, William E.; Harrison, Charles R.; Lahm, George P.; Piotrowski,  
 David W.; Wing, Keith D.  
 PA E. I. Du Pont de Nemours & Co., USA  
 SO U.S., 66 pp., Cont.-in-part U. S. 812, 200, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5500438	A	19960319	US 1993-146210	19931122
	EP 781768	A1	19970702	EP 1996-119940	19920515
	EP 781768	B1	20011121		
	R: DE, FR, IT				
	US 5602126	A	19970211	US 1995-562131	19951122
	JP 2001097956	A	20010410	JP 2000-223499	20000725
	JP 3257784	B2	20020218		
PRAI	US 1991-705428	B2	19910524		
	US 1991-744759	B2	19910814		
	US 1991-812200	B2	19911220		
	EP 1992-912790	A3	19920515		
	JP 1993-500115	A3	19920515		
	US 1993-146210	A3	19931122		
OS	MARPAT 125:10861				
GI					

AB Substituted anilides of the formula 4-R1C6H4NYCOQ are claimed, where Q is one of I-III and R1 = e.g., Cl, Br, CF3; R2 = e.g., H, halo, CF3; Y = e.g., C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl; R3 = e.g., CO2Me, CO2Et, Ph; R5 = e.g., H, C1-3 alkyl; Z = e.g., CH2, O, S, NR6; Z1 = e.g., O, NR11; R6 = e.g., H, C1-4 alkyl; R11 = e.g., H, C1-4 alkyl; arthropodocidal compns. containing such compds.; and a method for controlling arthropods by use of such compds. Thus, e.g., methylation of Me 2,3-dihydro-7-(trifluoromethyl)-2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-[1]benzopyrano[4,3-c]pyrazole-3a(4H)-carboxylate with NaH/MeI afforded 4-CF3C6H4NMeCOQ (Q = I with Z1 = O, R2 = 7-CF3, R3 = CO2Me) which exhibited  $\geq 80\%$  mortality against fall armyworm, tobacco budworm, southern corn rootworm, aster leafhopper, and boll weevil at 0.55 kg/ha.


IT 177096-32-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(arthropodicidal benzopyranopyrazole- and indenooxadiazine-derived anilides)

RN 177096-32-1 CAPLUS

CN Benzenepropanoic acid, 3-fluoro- $\alpha$ -(4-fluorophenyl)-, methyl ester  
(9CI) (CA INDEX NAME)



L7 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:634026 CAPLUS

DN 117:234026

TI Preparation of indenooxadiazinecarboxamides as arthropodicides

IN Annis, Gary David; Barnette, William Eldo; McCann, Stephen Frederick;  
Wing, Keith Dumont

PA du Pont de Nemours, E. I., and Co., USA

SO PCT Int. 01., 351 pp.

CODEN: P 02

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	ATE	APPLICATION NO.	DATE
PI	WO 921124	A1	9920709	WO 1991-US9164	199112.7
	W: A BB, BG, BR, C		CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO,		
	I RO, SD, SU, T				
	RW: A BE, BF, BJ, C		CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GM,		
	C IT, LU, MC, M		MR, NL, SE, SN, TD, TG		
	CA 209861	A1	9920622	CA 1991-2098612	199112.7
	CA 209861	C	0020507		
	AU 919127	A	9920722	AU 1991-91270	199112.7
	AU 659121	B2	9950511		
	EP 565574	A1	9931020	EP 1992-902235	199112.7
	EP 565574	B1	9950802		
	R: A BE, CH, DE, I		ES, FR, GB, GR, IT, LI, LU, MC, NL, SE		
	HU 65223	A2	9940502	HU 1993-1808	199112.7
	HU 213635	B	9970828		
	JP 065047	T	9940602	JP 1991-502714	199112.7
	BR 910724	A	9940614	BR 1991-7246	199112.7
	ES 207739	T3	9951116	ES 1992-902235	199112.7
	RU 209640	C1	9971120	RU 1991-5011055	199112.7
	ZA 911000	A	9930621	ZA 1991-10002	199112.9
	IL 100429	A	9960119	IL 1991-100429	199112.9
	CN 106272	A	9920715	CN 1991-111730	199112.21
	CN 103440	B	9970409		
	US 546293	A	9951031	US 1993-75534	199306.18
	US 570817	A	9980113	US 1995-448086	199505.23
PRAI	US 1990-64438	A2	9901221		
	US 1991-74401	A2	9910611		
	WO 1991-US9164	A	199112.7		
	US 1993-75534	A3	199306.18		
OS	CASREACT 117:234026; MARPAT 117:234026				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. QC(:X)NYG and QX1C:NG [I and II; Q = Q1, Q2, etc.; A = H; E = H, C1-3 alkyl or AE = CH2, CH2CH2, O, S, SO, SO2, OCH2, SCH2, etc.; G = (substituted) Ph, -pyridyl, -pyrimidyl, -thienyl, etc.; X = O, S, NX2; X1 = Cl, Br, OR8, SR8, NR8R9; X2 = R8, OH, OR8, cyano, SO2R8, SO2Ph, etc.; Y = H, C1-6 (halo)alkyl, CH2Ph, C2-6 alkoxyalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-3 alkoxy, cyano, NO2, (substituted) Ph, etc.; Z = C, N; Z1 = O, S, NR31; R2 = H, (substituted) C1-6 alkyl, C2-6 (halo) alkenyl, C2-6 (halo)alkynyl, C3-6 (halo)cycloalkyl, halo, cyano, N3, etc. or R2R2 = OCH2O, OCF2O, OCH2CH2O, etc.; R3 = H, N3, NO2, halo, C1-6 (halo) alkyl, C2-6 alkenyl, (substituted) Ph, etc.; R4, R5 = H, C1-4 alkyl, etc.; R4R5 = O, S; R8 = (substituted) C1-3 alkyl, C2-4 (halo)alkenyl, (substituted) benzyl, etc.; R9 = H, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkoxycarbonyl, (substituted) Ph, -pyridyl or R8R9 = (CH2)4, (CH2)5, etc.; R31 = H, C1-4 alkyl, C2-4 alkanoyl, C2-4 alkoxycarbonyl] were prepared for use in controlling anthropods, e.g. insects, pests, acari, etc. Thus, 5-chloro-2-(4-chlorophenyl)-2,3-dihydro-2-hydroxy-1H-inden-1-one (preparation given) was treated with hydrazine then 4-CF3C6H4NCO to give hydrazinecarboxamide III. The latter was cyclized with CH2O and TosOH to

CAS ONLINE PRINTOUT


give title compound IV. IV at 0.55 kg/ha gave  $\geq 80\%$  control of *Spodoptera frugiperda* on wheat germ.

IT 144172-20-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as intermediate for arthropodicides)

RN 144172-20-3 CAPLUS

CN Benzenepropanoic acid, 3-chloro- $\alpha$ -(4-chlorophenyl)-, methyl ester  
(9CI) (CA INDEX NAME)



L7 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1977:601405 CAPLUS

DN 87:201405

TI Antimycotic imidazoles. 2. Synthesis and antimycotic properties of  
1-[2-(arylalkyl)-2-phenylethyl]-1H-imidazoles

AU Heeres, Jan; Mostmans, Jozef H.; Van Cutsem, Jan

CS Res. Lab., Janssen Pharm., Beerse, Belg.

SO Journal of Medicinal Chemistry (1977), 20(11), 1511-16


CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 87:201405

GI



I


AB 1-[2-(Arylalkyl)-2-phenylethyl]-1H-imidazoles I ( $R_n = 2\text{-Cl, -Br, -Me, 4-Cl, 2,4-, 2,6-Cl}_2$ ;  $R_{1n} = \text{H, 2-, 4-Cl, 4-Br, -OMe, 2,4-, 2,6-Cl}_2$ ;  $m = 1, 2$ ) were prepared from the corresponding  $R_n\text{C}_6\text{H}_5\text{-nCH}_2\text{CN}$  via successive alkylation with  $\text{X(CH}_2\text{)mC}_6\text{H}_5\text{-nR}_{1n}$  ( $\text{X} = \text{halo}$ ), conversion to the corresponding ester  $R_n\text{C}_6\text{H}_5\text{-nCH(CO}_2\text{R)(CH}_2\text{)mC}_6\text{H}_5\text{-nR}_{1n}$  ( $\text{R} = \text{Me, Et}$ ), and  $\text{NaBH}_4\text{-LiI}$  reduction to  $R_n\text{C}_6\text{H}_5\text{-nCH(CH}_2\text{OH)(CH}_2\text{)mC}_6\text{H}_5\text{-nR}_{1n}$ . These alcs. were mesylated and the products refluxed with imidazole in DMF to yield I which were active in vitro against dermatophytes, yeasts, other fungi, and gram-positive bacteria. Some were also active in vivo against *Candida albicans*.

IT 59667-36-6P 64008-32-8P 64008-33-9P  
64008-35-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation and reduction of)


RN 59667-3 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(2-chlorophenyl)-, methyl ester  
 (9CI) (CA INDEX NAME)




RN 64008-33-8 CAPLUS  
 CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(2-methylphenyl)-, methyl ester  
 (9CI) (CA INDEX NAME)



RN 64008-33-9 CAPLUS  
 CN Benzenepropanoic acid, 2,4-dichloro- $\alpha$ -(2-chlorophenyl)-, methyl ester  
 (9CI) (CA INDEX NAME)




RN 64008-35-1 CAPLUS  
 CN Benzenepropanoic acid,  $\alpha$ -(2-bromophenyl)-4-chloro-, methyl ester  
 (9CI) (CA INDEX NAME)



## CAS ONLINE PRINTOUT

IN Heeres, Jan; Backx, Leo J. J.; Mostmans, Joseph H.  
 PA Janssen Pharmaceutica N. V., Belg.  
 SO U.S., 16 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3927017	A	19751216	US 1974-483587	19740627
	US 3991201	A	19761109	US 1975-578777	19750519
PRAI	US 1974-483587	A3	19740627		
GI					




AB Imidazoles I [ $R_n = Cl, F, H, 2,4-, 2,6-Cl_2$ ;  $R_1 = \text{alkyl, allyl, cycloalkyl, } CH_2C_6H_5R_2, CH_2C_6H_4Cl_2-2,4, CH_2C_6H_4Cl_2-2,6$ ;  $R_2 = Cl, Br, 4-Me, 4-MeO, CH_2CH_2Ph$ ] (53 compds.), fungicides, bacteriostats, and bactericides at 0.1-100  $\gamma/ml$ , were prepared by treating benzeneacetonitriles II ( $R_3 = H$ ) with halides  $R_1X$ , hydrolyzing-esterifying II ( $R_3 = R_1$ ) with  $HCl$  in  $MeOH$  or  $EtOH$ , reducing the ester  $R_nC_6H_5-nCHR_1CO_2R_4$  ( $R_4 = Me, Et$ ) with  $NaBH_4$  over  $LiX$  in  $MeCN$ , mesylating the alc.  $R_nC_6H_5-nCHR_1CH_2OH$ , and treating the methanesulfonate with imidazole.

IT 59667-36-6

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (reduction of)

RN 59667-36-6 CAPLUS

CN Benzenepropanoic acid, 4-chloro- $\alpha$ -(2-chlorophenyl)-, methyl ester  
 (9CI) (CA INDEX NAME)



=> file reg

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE

ENTRY

75.09

SINCE FILE

ENTRY

-10.14

TOTAL

SESSION

406.20

TOTAL

SESSION

-26.52

FILE 'REGISTRY' ENTERED AT 11:10:55 ON 01 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

CAS ONLINE PRINTOUT

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 31 AUG 2007 HIGHEST RN 945948-91-4  
DICTIONARY FILE UPDATES: 31 AUG 2007 HIGHEST RN 945948-91-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10690844.str



chain nodes :

7 8 9 10 11 19 20 22 24

ring nodes :

1 2 3 4 5 6 12 13 14 15 16 17

chain bonds :

5-7 7-8 7-19 8-9 8-12 9-10 9-11 11-20

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17

exact/norm bonds :



CAS LINE PRINTOUT

7-10 9-11 11-20

extra bonds :

5-7 8-9 8-12

normal bonds :

1-2 2-3 3-4 4-5 5-6 12-13 12-14 13-14 14-15 15-16 16-17

G1:R Ak

G2:C ,CO2H,Ak

G3:X ,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,s BuO,t-BuO,NH2,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

11:SS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS

22:SS 23:Atom 24:CLASS 25:Atom

L8 STRUCTURE UPLOADED

=> s CSS

SAMPLE SEARCH INITIATED 11:11:22 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 468 TO ITERATE

100. PROCESSED 468 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8063 TO 10657

PROJECTED ANSWERS: 0 TO 0

L9 0 SEA CSS SAM L8

=> s

SAMPLE SEARCH INITIATED 11:11:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 468 TO ITERATE

100.0 PROCESSED 468 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 8063 TO 10657

PROJECTED ANSWERS: 4 TO 200

L10 4 SEA SSS SAM L8

=> d scan


L10 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Butanedioic acid, 2,3-bis[4-(trifluoromethyl)phenyl]-, diethyl ester,  
(R\*,S\*)- (9CI)

MF C22 H20 F6 O4

Relative stereochemistry.

CAS ONLINE PRINTOUT




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):d his  
'D HIS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".  
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d ide

L10 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 910615-69-9 REGISTRY  
ED Entered STN: 18 Oct 2006  
CN 1,2-Benzenediacetic acid,  $\alpha$ 1-[2-ethoxy-1-[2-(2-ethoxy-2-oxoethyl)phenyl]-2-oxoethyl]-, 1,2-diethyl ester (CA INDEX NAME)  
MF C28 H34 O8  
SR Other Sources  
Database: Wiley Subscription Services, Inc.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

=> d his

(FILE 'HOME' ENTERED AT 10:52:23 ON 01 SEP 2007)

FILE 'REGISTRY' ENTERED AT 10:52:35 ON 01 SEP 2007

L1 STRUCTURE UPLOADED  
L2 2 S L1

CAS ONLINE INTOUT

L3                      23 S L1 FUL

FILE 'PLUS' ENTERED AT 10:53:37 ON 01 SEP 2007

L4                      '0 S L3

L5                      STRUCTURE UPLOADED

FILE GISTRY' ENTERED AT 11:02:08 ON 01 SEP 2007

L6                    20   SEARCH   L1   CSS   SUB=L3   FULL

FILE 'PLUS' ENTERED AT 11:02:42 ON 01 SEP 2007

L7 13 S L6

FILE 'REGISTRY' ENTERED AT 11:10:55 ON 01 SEP 2007

L8                      STRUCTURE UPLOADED

L9                      0 S L8 CSS

L10                      4 S L8

$$\Rightarrow d \mid e \quad b \quad 1-4$$

L10 ANSWER: . OF 4 REGISTRY COPYRIGHT 2007 ACS on STN

RN 91061 49-9 REGISTRY


ED      Enter      STN:    18 Oct 2006

CN 1,2-Bis (benzodiacetic acid,  $\alpha$ 1-[2-ethoxy-1-[2-(2-ethoxy-2-oxoethyl)phenyl]-2-oxoethyl]-, 1,2-diethyl ester (CA INDEX NAME)

MF C28 H . 08

SR Other sources

Data source: Wiley Subscription Services, Inc.



\*\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*\*

L10 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN

RN 144633-02-3 REGISTRY

ED Entered STN: 25 Nov 1992

CN Butanedioic acid, 2,3-bis[4-(trifluoromethyl)phenyl]-, diethyl ester,  
(R\*,S\*)- (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C22 H20 F6 O4

SR CA

LC STN Files: CA, CAPLUS, CHEMINFORMRX

Relative stereochemistry.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 117:251025 CA  
TI Electrochemistry of ethyl  $\alpha$ -bromo- $\alpha$ -fluoro(phenyl)acetate and some ethyl  $\alpha$ -bromo(trifluoromethylphenyl)acetates and electrochemical synthesis of the corresponding diastereoisomeric diethyl succinates  
AU Mattiello, Leonardo; Rampazzo, Liliana; Sotgiu, Giovanni  
CS Dip. ICMMPM, Univ. Roma 'La Sapienza', Rome, 00161, Italy  
SO Journal of Chemical Research, Synopses (1992), (10), 321  
CODEN: JRPSDC; ISSN: 0308-2342  
DT Journal  
LA English

L10 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN  
RN 70334-45-1 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Benzenepropanoic acid,  $\beta$ -(3,3-dimethyl-2-oxobutyl)-4-(1-methylethyl)- $\alpha$ -[4-(1-methylethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)  
MF C29 H40 O3  
LC STN Files: CA, CAPLUS, CASREACT



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1


AN 90:203702 CA  
TI 5-Oxopentanoic acid derivatives  
IN Fisnerova, Ludmila; Nemecek, Oldrich; Grimova, Jaroslava  
PA Czech.

## CAS ONLINE PRINTOUT

SO Czech., 6 pp.  
 CODEN: CZXXA9  
 DT Patent  
 LA Czech  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CS 176744	B1	19770630	CS 1975-2824	19750423
PRAI	CS 1975-2824		19750423		

L10 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 31249-04-4 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Succinic acid, 2,3-dicyano-2,3-di-p-tolyl-, didodecyl ester (8CI) (CA INDEX NAME)  
 MF C44 H64 N2 O4  
 LC STN Files: CA, CAPLUS, IFICDB, IFIPAT, IFIUDB, USPATOLD



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

## REFERENCE 1

AN 74:88362 CA  
 TI 1,2-Diphenyl-1,2-dicyano-1,2-bis[alkyl (or aryl or amino)peroxy (or oxy) carbonyl]ethanes as polymerization initiators  
 IN De Jongh, Hendrik A.; De Jonge, Cornelis R. H. I.  
 PA AKZO N. V.  
 SO Ger. Offen., 18 pp.  
 CODEN: GWXXBX  
 DT Patent  
 LA German  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2033910	A	19710121	DE 1970-2033910	19700708
	DE 2033910	B2	19810219		
	DE 2033910	C3	19811217		
	NL 6910428	A	19710112	NL 1969-10428	19690708
	NL 161425	C	19800215		
	NL 161425	B	19790917		
	US 3726837	A	19730410	US 1970-52073	19700702
	GB 1270784	A	19720412	GB 1970-1270784	19700707
	BE 753154	A	19701216	BE 1970-753154	19700708
	FR 2054344	A5	19710416	FR 1970-25339	19700708
	AT 300346	B	19720725	AT 1970-6212	19700708
	JP 49045151	B	19741202	JP 1970-59171	19700708
	SE 371811	B	19741202	SE 1970-9465	19700708

CAS ONLINE PRINTOUT

PRAI NL 1969-10428 19690708

=> d his

(FILE 'HOME' ENTERED AT 10:52:23 ON 01 SEP 2007)

FILE 'REGISTRY' ENTERED AT 10:52:35 ON 01 SEP 2007

L1 STRUCTURE UPLOADED  
L2 ! 2 S L1  
L3 123 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:53:37 ON 01 SEP 2007

L4 70 S L3  
L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:02:08 ON 01 SEP 2007

L6 20 SEARCH L1 CSS SUB=L3 FULL

FILE 'CAPLUS' ENTERED AT 11:02:42 ON 01 SEP 2007

L7 13 S L6

FILE 'REGISTRY' ENTERED AT 11:10:55 ON 01 SEP 2007

L8 STRUCTURE UPLOADED  
L9 0 S L8 CSS  
L10 4 S L8

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	16.29	422.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-26.52

FILE 'CAPLUS' ENTERED AT 11:15:03 ON 01 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Sep 2007 VOL 147 ISS 11

FILE LAST UPDATED: 31 Aug 2007 (20070831/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l10

L11 3 L10

=&gt; d bib a.s k tstr 1-3

L11 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1992:0510'5 CAPLUS

DN 117:20102

TI Electrochemistry of ethyl  $\alpha$ -bromo- $\alpha$ -fluoro(phenyl)acetate and some ethyl  $\alpha$ -bromo(trifluoromethylphenyl)acetates and electrochemical synthesis of the corresponding diastereoisomeric diethyl succinates.

AU Mattiello, Leonardo; Rampazzo, Liliana; Sotgiu, Giovanni

CS Dip. ICMMEM, Univ. Roma 'La Sapienza', Rome, 00161, Italy


SO Journal of Chemical Research, Synopses (1992), (10), 321

CODEN: JRPSPDC; ISSN: 0308-2342

DT Journal

LA English

GI



AB Electrolysis of  $\text{PhCFBrCO}_2\text{Et}$  and title bromo(trifluoromethyl)phenylacetates I ( $\text{R}_1 = \text{CF}_3$ ,  $\text{R}_2\text{-R}_4 = \text{H}$ ;  $\text{R}_1 = \text{R}_3 = \text{R}_4 = \text{H}$ ,  $\text{R}_2 = \text{CF}_3$ ,  $\text{R}_1 = \text{R}_3 = \text{H}$ ,  $\text{R}_2 = \text{R}_4 = \text{CF}_3$ ;  $\text{R}_1 = \text{R}_2 = \text{R}_4 = \text{H}$ ,  $\text{R}_3 = \text{CF}_3$ ) on reticulated vitreous carbon in DMF gave dimers  $\text{PhCF}(\text{CO}_2\text{Et})\text{CF}(\text{CO}_2\text{Et})\text{Ph}$  and II. II were obtained as mixture of meso- and DL-forms.


IT 144633-02-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 144633-02-3 CAPLUS

CN Butanedioic acid, 2,3-bis[4-(trifluoromethyl)phenyl]-, diethyl ester,  
( $\text{R}^*$ ,  $\text{S}^*$ )- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L11 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1979:203702 CAPLUS

DN 90:203702


TI 5-Oxopentanoic acid derivatives

IN Fisnerova, Ludmila; Nemecek, Oldrich; Grimova, Jaroslava

PA Czech.

SO Czech., 6 pp.  
 CODEN: CZXXX  
 DT Patent  
 LA Czech  
 FAN.CNT 1

PATENT NO.	KIND	L	---	APPLICATION NO.	DATE
PT CS 176744	B1	1	630	CS 1975-2824	19750423
PRAI CS 1975-2824	A	1	423		
GI					




AB The title comds. I (R1 = H, 4 alkyl, Cl, NO2, OMe; R2 = H, CHMe2, NMe2, Cl, NO2; R3 = Ph, 2-furyl, CMe3, 3-indanyl, C6H3Cl2-2,4) were prepared by addition of 4-R1C6H4CH2CO2Et to 4-R2C6H4CH:CHCOR3 and saponification of the product. Thus, a solution of 4.6 g PhCH2CO2Et and 3.7 g 4-Me2CHC6H4CH:CHCOPh in Et2O containing EtONa was kept 5 days to give 4.4 g PhCOCH2CH(C6H4CHMe2-4)CHPhCO2Et which was refluxed with AcOH-HBr to yield 3.5 g I (R1 = H, R2 = CHMe2, R3 = Ph). Similarly prepared were PhCOCH2CH(R4)CH(R5)CO2H (R4 = 2-furyl, 3-pyridyl; R5 = Ph, C6H4NO2-4, C6H4CH2CHMe2-4).

IT 70334-45-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 70334-45-1 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -(3,4-dimethyl-2-oxobutyl)-4-(1-methylethyl)- $\alpha$ -[4-(1-methylethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1971:88362 CAPLUS

DN 74:88362

TI 1,2-Diphenyl-1,2-dicyano-1,2-bis[alkyl (or aryl or amino)peroxy (or oxy) carbonyl]ethanes as polymerization initiators

IN De Jongh, Hendrik A.; De Jonge, Cornelis R. H. I.

PA AKZO N. V.

SO Ger. Offen., 18 pp.  
 CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 1



## CAS ONLINE PRINTOUT

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2033910	A	19710121	DE 1970-2033910	19700708
	DE 2033910	B2	19810219		
	DE 2033910	C3	19811217		
	NL 6910428	A	19710112	NL 1969-10428	19690708
	NL 161425	C	19800215		
	NL 161425	B	19790917		
	US 3726837	A	19730410	US 1970-52073	19700702
	GB 1270784	A	19720412	GB 1970-1270784	19700707
	BE 753154	A	19701216	BE 1970-753154	19700708
	FR 2054344	A5	19710416	FR 1970-25339	19700708
	AT 300346	B	19720725	AT 1970-6212	19700708
	JP 49045151	B	19741202	JP 1970-59171	19700708
SE 371811	B	19741202	SE 1970-9465	19700708	
PRAI	NL 1969-10428	A	19690708		
AB	The reaction-specific, fairly heat-stable compds. of the formula NC(p-R C6H4) [R1(O)nOC]CC[CO(O)nR1] (C6H4R-p)CN (I), where R = H, Me, Cl, NO2, or OMe; R1 = Me, Et, Ph, NH2, NHMe, or pipe ridino, n = 0-1, oxidation resistant, of relatively high activity at lower temps., inactive at room temperature, and which do not form gaseous products during radical formation				
are	useful as radical initiators for polymerization, e.g., of styrene (II), AcOCH:CH2, CH2:CHCN, or CH2:CMeCO2Me, or the hardening, e.g., of the unsatd. polyester resin Lupodal P-6. I are prepared by treating the corresponding NC(p-RC6H4)CH[CO(O)nR1] with O in the presence of CuCl and Me2NCH2CH2NMe2.				
IT	31249-04-4	RL: CAT (Catalyst use); USES (Uses) (catalysts, for polymerization of vinyl compds.)			
RN	31249-04-4	CAPLUS			
CN	Succinic acid, 2,3-dicyano-2,3-di-p-tolyl-, didodecyl ester (8CI) (CA INDEX NAME)				



=&gt; file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

19.10

441.59

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.34

-28.86

FILE 'REGISTRY' ENTERED AT 11:19:25 ON 01 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file

CAS ONLINE <INTOUT

provided by InfoChem.

STRUCTURE FILE UPDATES: JG 2007 HIGHEST RN 945948-91 4  
DICTIONARY FILE UPDATES: JG 2007 HIGHEST RN 945948-91 4

New CAS Information Use Pages, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerical searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/egen/stndoc/properties.html>

=> d his

(FILE 'HOME' ENTERED AT 10:52:23 ON 01 SEP 2007)

L1 FILE 'REGISTRY' ENTERED AT 10:52:35 ON 01 SEP 2007  
L2 STRUCTURE UNLOADED  
L3 2 S L1  
L3 123 S L1 FUL

L4 FILE 'CAPLUS' ENTERED AT 10:53:37 ON 01 SEP 2007  
L5 70 S L3  
L5 STRUCTURE UNLOADED

L6 FILE 'REGISTRY' ENTERED AT 11:02:08 ON 01 SEP 2007  
L6 20 SEARCH L1 (SUB=L3 FULL

L7 FILE 'CAPLUS' ENTERED AT 11:02:42 ON 01 SEP 2007  
L7 13 S L6

L8 FILE 'REGISTRY' ENTERED AT 11:10:55 ON 01 SEP 2007  
L8 STRUCTURE UNLOADED  
L9 0 S L8 CSS  
L10 4 S L8

L11 FILE 'CAPLUS' ENTERED AT 11:15:03 ON 01 SEP 2007  
L11 3 S L10

FILE 'REGISTRY' ENTERED AT 11:19:25 ON 01 SEP 2007

=> s l8 ful

FULL SEARCH INITIATED 11:19:36 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 9516 TO ITERATE

100.0% PROCESSED 9516 ITERATIONS 136 ANSWERS  
SEARCH TIME: 00.00.01

L12 136 SEA SSS FUL L8

=> file uspatful

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	613.69

CAS ONLINE PRINTOUT

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-28.86

FILE 'USPATFULL' ENTERED AT 11:19:45 ON 01 SEP 2007  
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 Aug 2007 (20070830/PD)  
FILE LAST UPDATED: 30 Aug 2007 (20070830/ED)  
HIGHEST GRANTED PATENT NUMBER: US7263724  
HIGHEST APPLICATION PUBLICATION NUMBER: US2007204372  
CA INDEXING IS CURRENT THROUGH 30 Aug 2007 (20070830/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 Aug 2007 (20070830/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2007  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2007

=> s l12

L13 15 L12

=> d his

(FILE 'HOME' ENTERED AT 10:52:23 ON 01 SEP 2007)

FILE 'REGISTRY' ENTERED AT 10:52:35 ON 01 SEP 2007

L1 STRUCTURE UPLOADED

L2 2 S L1

L3 123 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:53:37 ON 01 SEP 2007

L4 70 S L3

L5 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 11:02:08 ON 01 SEP 2007

L6 20 SEARCH L1 CSS SUB=L3 FULL

FILE 'CAPLUS' ENTERED AT 11:02:42 ON 01 SEP 2007

L7 13 S L6

FILE 'REGISTRY' ENTERED AT 11:10:55 ON 01 SEP 2007

L8 STRUCTURE UPLOADED

L9 0 S L8 CSS

L10 4 S L8

FILE 'CAPLUS' ENTERED AT 11:15:03 ON 01 SEP 2007

L11 3 S L10

FILE 'REGISTRY' ENTERED AT 11:19:25 ON 01 SEP 2007

L12 136 S L8 FUL

FILE 'USPATFULL' ENTERED AT 11:19:45 ON 01 SEP 2007

L13 15 S L12

=> d bib abs hitstr 1-15

L13 ANSWER 1 OF 15 USPATFULL on STN

AN 2007:155411 USPATFULL


TI HETEROCYCLIC CETP INHIBITORS

IN Salvati, Mark E., Lawrenceville, NJ, UNITED STATES

Finlay, Heather, Skillman, NJ, UNITED STATES

## CAS ONLINE PRINTOUT

Chen, Bang-Chi, Plainfield, NJ, UNITED STATES  
 Harikrishnan, Lalgudi, Princeton, UNITED STATES  
 Jiang, Ji, West Windsor, NJ, UNITED STATES  
 Johnson, James A., Pennington, NJ, UNITED STATES  
 Kamau, Muthoni G., Lawrenceville, NJ, UNITED STATES  
 Lawrence, R. Michael, Ardley, PA, UNITED STATES  
 Li, Jianqing, Guilford, CT, UNITED STATES  
 Lloyd, John, Yardley, PA, UNITED STATES  
 Miller, Michael M., Pennington, NJ, UNITED STATES  
 Pi, Zulan, Pennington, NJ, UNITED STATES  
 Qiao, Jennifer X., Princeton, NJ, UNITED STATES  
 Rampulla, Richard A., Flemington, NJ, UNITED STATES  
 Roberge, Jacques Y., Princeton, NJ, UNITED STATES  
 Wang, Tammy C., Lawrenceville, NJ, UNITED STATES  
 Wang, Yufeng, North Brunswick, NJ, UNITED STATES  
 Yang, Wu, Princeton Junction, NJ, UNITED STATES  
 PA Bristol-Myers Squibb Company (U.S. corporation)  
 PI US 2007135631 A 20070614  
 AI US 2006-558979 A 20061113 (11)  
 PRAI US 2005-739374P 2 51123 (60)  
 DT Utility  
 FS APPLICATION  
 LREP LOUIS J. WILLE, BRISTOL-MYERS SQUIBB ANY, PATENT DEPARTMENT, P O BOX  
 4000, PRINCETON, NJ, 08543-4000, US  
 CLMN Number of Claims: 23  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 21135  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB Compounds of formula Ia and Ib ##S =# wherein A, B, C and R.sub.1  
 are described herein.  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 IT 939399-31-2P  
 (preparation of heterocyclic and aromatic ureas and amides as CEPT  
 inhibitors  
 for treating, preventing or slowing the progression of a disease  
 requiring cholesteryl ester transfer protein inhibitor therapy)  
 RN 939399-31-2 USPATFULL  
 CN Benzenepropanoic acid, 4-bromo- $\alpha$ -[3-fluoro-5-(1,1,2,2-  
 tetrafluoroethoxy)phenyl]- $\alpha$ -[4-fluoro-2-(trifluoromethyl)phenyl]-,  
 methyl ester (CA INDEX NAME)



L13 ANSWER 2 OF 15 USPATFULL on STN

AN 2005:255715 USPATFULL

TI Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents

IN Zhao, Zuchun, Pleasanton, CA, UNITED STATES

Chen, Xin, San Ramon, CA, UNITED STATES

Wang, Jianchao, Castro Valley, CA, UNITED STATES

Sun, Hongbin, Hayward, CA, UNITED STATES

Liang, Jack Shih-Chieh, Mountain View, CA, UNITED STATES

PA Metabolex, Inc., Hayward, CA, UNITED STATES (U.S. corporation)

PI US 2005222213 A1 20051006

AI US 2005-61302 A1 20050217 (11)

PRAI US 2004-545850P 20040218 (60)

DT Utility

FS APPLICATION

LREP TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US

CLMN Number of Claims: 21

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2655

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds having a formula: ##STR1## or a pharmaceutically acceptable salt or prodrug thereof, are provided, and are useful for the treatment of metabolic disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 863423-21-6P

(drug candidate; preparation of trifluoromethylphenyl-substituted acetic acid derivs. for treating inflammation and metabolic disorders)

RN 863423-21-6 USPATFULL

CN Benzenepropanoic acid, 3-(trifluoromethyl)- $\alpha$ -[4-(trifluoromethyl)phenyl]-, 2-(acetylamino)ethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 3 OF 15 USPATFULL on STN

AN 2005:152100 USPATFULL

TI Quinolines useful in treating cardiovascular diseases

IN Collini, Michael D., Clifton Heights, PA, UNITED STATES

Singhaus, Robert R. JR., Pottstown, PA, UNITED STATES

Hu, Baihua, Audubon, PA, UNITED STATES

Jetter, James W., Norristown, PA, UNITED STATES

Morris, Robert L., Wayne, PA, UNITED STATES

Kaufman, David H., Schwenksville, PA, UNITED STATES

Miller, Christopher P., Wayne, PA, UNITED STATES

Ullrich, John W., Exton, PA, UNITED STATES

Unwalla, Rayomand J., Eagleville, PA, UNITED STATES

Wrobel, Jay E., Lawrence, NJ, UNITED STATES

Quinet, Elaine, Berwyn, PA, UNITED STATES

Nambi, Ponnal, Berwyn, PA, UNITED STATES

Bernotas, Ronald C., Royersford, PA, UNITED STATES

Elloso, Merle, Devon, PA, UNITED STATES

PA Wyeth, Madison, NJ, UNITED STATES, 07940 (U.S. corporation)

PI US 2005131014 A1 20050616

AI US 2004-10236 A1 20041210 (11)

PRAI US 2003-529009P 20031212 (60)

US 2004-600296P 20040810 (60)

DT Utility

FS APPLICATION

LREP COZEN O' CONNOR, P. C., 1900 MARKET STREET, PHILADELPHIA, PA,  
19103-3508, US

CLMN Number of Claims: 31

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 12710

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB This invention provides compounds of formula I ##STR1## that are  
useful in the treatment or inhibition of LXR mediated diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 854771-85-0P, Methyl 2-[4-[[3-[3-Benzoyl-8-(Trifluoromethyl)Quinolin-4-yl]Phenoxy]Methyl]Phenyl]-3-[4-(2-Methoxy-2-Oxoethyl)Phenyl]Propanoate  
(drug candidate; preparation of quinolines useful in treating LXR (liver X  
receptor)-mediated diseases)

RN 854771-85-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[4-[[3-[3-benzoyl-8-(trifluoromethyl)-4-quinolinyl]phenoxy]methyl]phenyl]-4-(2-methoxy-2-oxoethyl)-, methyl  
ester (9CI) (CA INDEX NAME)



L13 ANSWER 4 OF 15 USPATFULL on STN  
 AN 2004:168045 USPATFULL  
 TI Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them  
 IN Defossa, Elisabeth, Idstein, GERMANY, FEDERAL REPUBLIC OF  
 Heinelt, Uwe, Wiesbaden, GERMANY, FEDERAL REPUBLIC OF  
 Klingler, Otmar, Rodgau, GERMANY, FEDERAL REPUBLIC OF  
 Zoller, Gerhard, Schoneck, GERMANY, FEDERAL REPUBLIC OF  
 Matter, Hans, Langenselbold, GERMANY, FEDERAL REPUBLIC OF  
 Al-Obeidi, Fahad A., Tucson, AZ, United States  
 Walser, Armin, Tucson, AZ, United States  
 Wildgoose, Peter, Oberursel, GERMANY, FEDERAL REPUBLIC OF  
 PA Aventis Pharma Deutschland GmbH, Frankfurt am Main, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)  
 PI US 6759420 B1 20040706  
 AI US 1999-472936 19991228 (9)  
 PRAI EP 1999-100001 19990102  
 EP 1999-119538 19991001  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Chang, Ceila; Assistant Examiner: Robinson, Binta  
 LREP Finnegan, Henderson, Farabow, Garrett, & Dunner, L.L.P.  
 CLMN Number of Claims: 27  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 4141

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to new compounds for the inhibition of blood clotting proteins and factor Xa activity, and more particularly, to arylalkanoyl derivatives of the formula (I): ##STR1##

wherein R(1), R(2), R(3), R(4), R(5), R(6a), and R(6b) have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (I), to methods of inhibiting factor Xa activity and of inhibiting blood clotting, to the use of the compounds of formula (I) in the treatment and prophylaxis of diseases which can be treated or prevented by the inhibition of factor Xa activity, such as cardiovascular or thromboembolic diseases, and to the use of the compounds of formula (I) in the preparation of medicaments to be applied in such diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 283162-06-1P 283162-07-2P

(preparation of arylalkanoylaminoacetamides as blood coagulation factor Xa inhibitors)

RN 283162-06-1 USPATFULL


CAS ONLINE PRINTOUT

CN Benzenepropanoic acid, 4-[(hydroxyamino)iminomethyl]- $\alpha$ -[3-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 283162-07-2 USPATFULL

CN Benzenepropanoic acid, 4-[[[(ethoxycarbonyloxy)amino]iminomethyl]- $\alpha$ -[3-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 5 OF 15 USPATFULL on STN

AN 2004:95423 USPATFULL

TI 2,3-Diphenylpropionic acid derivatives or their salts, medicines or cell adhesion inhibitors containing the same, and their usage

IN Hoshina, Yoichiro, Kyoto, JAPAN  
Ikegami, Satoru, Kyoto, JAPAN  
Okuyama, Akihiko, Kyoto, JAPAN  
Harada, Tatsuhiko, Kyoto, JAPAN  
Matsuo, Atsushi, Shizuoka, JAPAN

PI US 2004072878 A1 20040415

AI US 2003-344105 A1 20030819 (10)  
WO 2001-JP6934 20010810

PRAI JP 2000-244226 20000811  
JP 2001-115840 20010413

DT Utility

FS APPLICATION

LREP NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA, 22201-4714

CLMN Number of Claims: 15

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 3901

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A 2,3-diphenylpropionic acid derivatives or the salts represented by general formula (1) below; and pharmaceutical compositions and cell adhesion inhibitors comprising the derivatives or the salts as the active ingredient. In the formula, A, B and C independently represents a hydrogen atom or a monovalent substituent; and X and X' independently represents a hydrogen atom or a monovalent substituent. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 400648-72-8P

(preparation of 2,3-diphenylpropionic acid derivs. or their salts as cell adhesion inhibitors, integrin antagonists or inhibitors, and antiinflammatory agents)



CAS ONL. PRINTOUT

RN 40- 4-72-8 USPATFULL  
CN Benzenepropanoic acid,  $\alpha$ -[3-[(2,2-dimethyl-1-oxopropyl)(2-  
methylpropyl)amino]-4-ethylphenyl]-4-nitro-, ethyl ester (9CI) (CA  
INDEX NAME)



L13 ANSWER 6 OF 15 USPATFULL on STN  
AN 2:13:258441 USPATFULL  
TI Novel heterocyclic analogs of diphenylethylene compounds  
IN Nengi, Partha, Fremont, CA, UNITED STATES  
Devi, Debendranath, Fremont, CA, UNITED STATES  
Methicherla, Satyanarayana, Cupertino, CA, UNITED STATES  
Nagi, Bishwajit, Union City, CA, UNITED STATES  
Lee, Arthur, San Francisco, CA, UNITED STATES  
PI US 2003181494 A1 20030925  
AI US 2002-265902 A1 20021008 (10)  
RLI Continuation-in-part of Ser. No. US 2001-843167, filed on 27 Apr 2001,  
PENDING Continuation-in-part of Ser. No. US 2001-785554, filed on 20 Feb  
2001, PENDING Continuation-in-part of Ser. No. US 2000-591105, filed on  
9 Jun 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-287237,  
filed on 6 Apr 1999, GRANTED, Pat. No. US 6331633  
DT Utility  
FS APPLICATION  
LREP PILLSBURY WINTHROP, LLP, P.O. BOX 10500, MCLEAN, VA, 22102  
CLMN Number of Claims: 40  
ECL Exemplary Claim: 1  
DRWN 26 Drawing Page(s)  
LN.CNT 2827  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB Novel diphenylethylene compounds and derivatives thereof containing  
thiazolidinedione or oxazolidinedione moieties are provided which are  
effective in lowering blood glucose level, serum insulin, triglyceride  
and free fatty acid levels in animal models of Type II diabetes. The  
compounds are disclosed as useful for a variety of treatments including  
the treatment of inflammation, inflammatory and immunological diseases,  
insulin resistance, hyperlipidemia, coronary artery disease, cancer and  
multiple sclerosis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 380881-43-6P

(preparation of diphenylethylene compds. containing thiazolidinedione or  
oxazolidinedione moieties for treating diabetes, inflammatory or  
immunol. disease in combination with other agents)

RN 380881-43-6 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -(4-hydroxyphenyl)-3,5-dimethoxy-, methyl  
ester (9CI) (CA INDEX NAME)



L13 ANSWER 7 OF 15 USPATFULL on STN  
 AN 2003:243897 USPATFULL  
 TI Use of polymeric reaction product  
 IN Raether, Roman Benedikt, Limburgerhof, GERMANY, FEDERAL REPUBLIC OF  
 Brinkmann-Rengel, Susanne, Ober-Olm, GERMANY, FEDERAL REPUBLIC OF  
 Haremza, Sylke, Neckargemund, GERMANY, FEDERAL REPUBLIC OF  
 PI US 2003170306 A1 20030911  
 US 7008990 B2 20060307  
 AI US 2003-311378 A1 20030421 (10)  
 WO 2001-EP6712 20010613  
 PRAI DE 2000-10029694 20000616  
 DT Utility  
 FS APPLICATION  
 LREP KEIL & WEINKAUF, 1350 CONNECTICUT AVENUE, N.W., WASHINGTON, DC, 20036  
 CLMN Number of Claims: 7  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 2511

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A reaction product (A) which can be prepared by reaction, under free radical conditions, of at least one monomer (a) capable of free radical reaction, in the presence of at least one free radical initiator and of a radical of the formula (III) ##STR1##

where R.sub.1 to R.sub.3, in each case independently of one another, are hydrogen, methyl or a radical-stabilizing and/or bulky group selected from an unsubstituted or substituted, linear or branched alkyl of two or more carbon atoms, cycloalkyl, alcohol, ether, polyether, amine, aralkyl radical, a substituted or unsubstituted aromatic, heterocyclic or olefinic hydrocarbon, a halogen atom, a substituted or unsubstituted, linear or branched alkenyl or alkynyl group, --C(O)R.sub.5, --C(O)OR.sub.5, --CR.sub.5R.sub.6--O--R.sub.7, --O--C(O)R.sub.5, --CN, --O--CN, --S--CN, --O--C.dbd.NR.sub.5, --S--C.dbd.NR.sub.5, --O--CR.sub.5R.sub.6--CR.sub.7R.sub.8NR.sub.9R.sub.10, --N.dbd.C.dbd.O, --C.dbd.NR.sub.5, --CR.sub.5R.sub.6--Hal, --C(S)R.sub.5, --CR.sub.5R.sub.6--P(O)R.sub.7R.sub.8, --CR.sub.5R.sub.6--PR.sub.7R.sub.8, --CR.sub.5R.sub.6--NR.sub.7R.sub.8, --CR.sub.5R.sub.6(OR.sub.7)(OR.sub.8), --CR.sub.5R.sub.6(OR.sub.7)(NR.sub.8), --CR.sub.5R.sub.6(NR.sub.7)(NR.sub.8), an anhydride, acetal or ketal group, --SO.sub.2R.sub.5, an amidine group, --NR.sub.5C(S)NR.sub.6, --NR.sub.5C(S)--OR.sub.6, --N.dbd.C.dbd.S, --NO.sub.2, --C.dbd.N--OH, --N(R.sub.5).dbd.NR.sub.6, --PR.sub.5R.sub.6R.sub.7, --OSiR.sub.5R.sub.6R.sub.7 or --SiR.sub.5R.sub.6R.sub.7, where R.sub.5 to R.sub.10, independently of one another in each case, are defined in the same way as R.sub.1 to R.sub.5, or two of the radicals R.sub.1 to R.sub.4 form a C.sub.4- to C.sub.7-ring which in turn may be substituted or unsubstituted and, if required, may contain one or more heteroatoms, with the proviso that at least two of the radicals R.sub.1 to R.sub.3 are a radical-stabilizing and/or bulky group as defined above, has various uses.

CAS ONLINE PRINTOUT


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 70230-43-2

(block copolymers obtained by radical polymerization of monomers in presence of radicals bearing radical-stabilizing or bulky substituents)

RN 70230-43-2 USPTAFULL

CN Butanedioic acid, 1,3-dicyano-2,3-bis(4-methylphenyl)-, diethyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 8 OF 15 USPTAFULL on STN

AN 2002:55062 USPTAFULL

TI Novel heterocyclic analogs of diphenylethylene compounds

IN Nag, Bishwajit, Fremont, CA, UNITED STATES

Dey, Debendranath, Fremont, CA, UNITED STATES

Medicherla, Sattanarayana, Cupertino, CA, UNITED STATES

Neogi, Partha, Fremont, CA, UNITED STATES

PI US 2002032225 A1 20020314

US 7105552 B2 20060912

AI US 2001-843167 A1 20010427 (9)

RLI Continuation-in-part of Ser. No. US 2001-785554, filed on 20 Feb 2001, PENDING Continuation-in-part of Ser. No. US 2000-591105, filed on 9 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-287237, filed on 6 Apr 1999, PENDING Continuation-in-part of Ser. No. US 1998-74925, filed on 8 May 1998, GRANTED, Pat. No. US 6245814

DT Utility

FS APPLICATION

LREP Pillsbury Winthrop LLP, Intellectual Property Group, 1600 Tysons Boulevard, McLean, VA, 22102

CLMN Number of Claims: 60

ECL Exemplary Claim: 1

DRWN 14 Drawing Page(s)

LN.CNT 1388

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 380881-43-6P, 3-(3,5-Dimethoxyphenyl)-2-(4-hydroxyphenyl)propionic acid methyl ester

(intermediate; preparation of novel heterocyclic analogs of phenylethylene compds. as inhibitors of cytokines or cyclooxygenase for therapeutic agents)

RN 380881-43-6 USPTAFULL

CAS ONLINE PRINTOUT

CN Benzenepropanoic acid,  $\alpha$ -(4-hydroxyphenyl)-3,5-dimethoxy-, methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 9 OF 15 USPATFULL on STN

AN 89:69875 USPATFULL

TI Terpyridine chelating agents

IN Toner, John L., Webster, NY

PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

PI US 4859777 19890822

AI US 1988-285163 19881216 (7)

RLI Division of Ser. No. US 1987-40385, filed on 20 Apr 1987 which is a continuation-in-part of Ser. No. US 1987-7024, filed on 27 Jan 1987, now patented, Pat. No. US 4801722 which is a division of Ser. No. US 1986-825693, filed on 3 Feb 1986, now patented, Pat. No. US 4637988 which is a continuation of Ser. No. US 1981-279398, filed on 1 Jul 1981, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Everett, John R.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 742

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described stable fluorescent labels comprising a complex of Eu.sup.+3 and a chelating agent comprising a nucleus which is a triplet sensitizer having a triplet energy greater than that of Eu.sup.+3 and at least two heteroatom-containing groups which form coordinate complexes with Eu.sup.+3 and a third heteroatom-containing group or heteroatom in or appended to the triplet sensitizer. Labeled physiologically active materials useful in specific binding assays such as labeled antigens, haptens, antibodies, hormones and the like comprising the stable fluorescent labels having physiologically active materials adsorbed or bonded thereto are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 85929-38-0P

(preparation and hydrolysis of)

RN 85929-38-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)



I


OH

IT 85916-19-4P

(preparation of)

RN 85916-19-4 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[3,5-bis[[bis(carboxymethyl)amino]methyl]-4-hydroxybenzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-,  $\alpha$ -methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 10 OF 15 USPATFULL on STN

AN 89:45508 USPATFULL

TI Polypyridine Fluorescent labels for immunoassay

## CAS ONLINE PRINTOUT

IN Toner, John L., Webster, NY, United States  
 PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
 PI US 4837169 19890606  
 AI US 1987-40385 19870420 (7)  
 RLI Continuation-in-part of Ser. No. US 1987-7024, filed on 27 Jan 1987  
 which is a division of Ser. No. US 1986-825693, filed on 3 Feb 1986, now  
 patented, Pat. No. US 4637988 which is a continuation of Ser. No. US  
 1981-279398, filed on 1 Jul 1981, now abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Schwartz, Richard A.  
 LREP Everett, John R.  
 CLMN Number of Claims: 16  
 ECL Exemplary Claim: 16  
 DRWN No Drawings  
 LN.CNT 865

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described stable fluorescent labels comprising a complex of  
 Eu.sup.+3 and a chelating agent comprising a nucleus which is a triplet  
 sensitizer having a triplet energy greater than that of Eu.sup.+3 and at  
 least two heteroatom-containing groups which form coordinate complexes  
 with Eu.sup.+3 and a third heteroatom-containing group or heteroatom in  
 or appended to the triplet sensitizer. Labeled physiologically active  
 materials useful in specific binding assays such as labeled antigens,  
 haptens, antibodies, hormones and the like comprising the stable  
 fluorescent labels having physiologically active materials adsorbed or  
 bonded thereto are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 85929-38-0P

(preparation and hydrolysis of)

RN 85929-38-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-  
 dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-  
 diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



I


OH

IT 85916-19-4P

(preparation of)

RN 85916-19-4 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[3,5-bis[[bis(carboxymethyl)amino]methoxy]-4-hydroxybenzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-,  $\alpha$ -methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 11 OF 15 USPATFULL on STN

AN 89:7688 USPATFULL

TI Coumarin chelates

IN Hinshaw, Jerald C., Ogden, UT, United States

Toner, John L., Webster, NY, United States

Reynolds, George A., Rochester, NY, United States

PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

PI US 4801722 19890131

AI US 1987-7024 19870127 (7)

RLI Division of Ser. No. US 1986-825693, filed on 3 Feb 1986, now patented, Pat. No. US 4637988 which is a continuation of Ser. No. US 1981-279398, filed on 1 Jul 1981, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Everett, John R.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 739

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described stable fluorescent labels comprising a complex of lanthanide metal and a chelating agent comprising a nucleus which is a triplet sensitizer having a triplet energy greater than that of said

1. 2. 3. 4.

lanthanide metal and at least two heteroatom-containing groups which form coordinate complexes with lanthanide metals and a third heteroatom-containing group or heteroatom in or appended to the triplet sensitizer. Labeled physiologically active materials useful in specific binding assays such as labeled antigens, heptens, antibodies, hormones and the like comprising the stable fluorescent labels having physiologically active materials adsorbed or bonded thereto are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 85929-38-0F

(preparation and hydrolysis of)

RN 85929-38-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

I

 $\text{—OH}$ 


IT 85916-19-4P

(preparation of)

RN 85916-19-4 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[3,5-bis[[bis(carboxymethyl)amino]methyl]-4-hydroxybenzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-,  $\alpha$ -methyl ester (9CI) (CA INDEX NAME)





L13 ANSWER 12 OF 15 USPATFULL on STN

AN 88:83978 USPATFULL

TI Fluorescent chelates

IN Hinshaw, Jerald C., Ogden, UT, United States

Toner, John L., Webster, NY, United States

Reynolds, George A., Rochester, NY, United States

PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)

PI US 4794191 19881227

AI US 1988-151847 19880203 (7)

RLI Division of Ser. No. US 1987-7024, filed on 27 Jan 1987 which is a division of Ser. No. US 1986-825693, filed on 3 Feb 1986, now patented, Pat. No. US 4637988 which is a continuation of Ser. No. US 1981-279398, filed on 1 Jul 1981, now abandoned

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Everett, John R.

CLMN Number of Claims: 1

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 738

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described stable fluorescent labels comprising a complex of lanthanide metal and a chelating agent comprising a nucleus which is a triplet sensitizer having a triple energy greater than that of said lanthanide metal and at least two heteroatom-containing groups which form coordinate complexes with lanthanide metals and a third heteroatom-containing group or heteroatom in or appended to the triplet sensitizer. Labeled physiologically active materials useful in specific binding assays such as labeled antigens, heptens, antibodies, hormones and the like comprising the stable fluorescent labels having physiologically active materials adsorbed or bonded thereto are also described.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 85929-38-0P

(preparation and hydrolysis of)


RN 85929-38-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)



I  
OH

IT 85916-19-4P  
(preparation of)  
RN 85916-19-4 USPATFULL  
CN Benzenepropanoic acid, α-[3-[3,5-bis[[bis(carboxymethyl)amino]methyl]-4-hydroxybenzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, α-methyl ester (9CI) (CA INDEX NAME)



L13 ANSWER 13 OF 15 USPATFULL on STN  
AN 87:40012 USPATFULL  
TI Phenolic fluorescent labels

## CAS ONLINE PRINTOUT

IN Hinshaw, Jerald C., Ogden, UT, United States  
Toner, John L., Webster, NY, United States  
Reynolds, George A., Rochester, NY, United States  
PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
PI US 4670572 19870602  
AI US 1986-825009 19860203 (6)  
RLI Division of Ser. No. US 1981-279398, filed on 1 Jul 1981, now abandoned  
DT Utility  
FS Granted  
EXNAM Primary Examiner: Schwartz, Richard A.  
LREP Everett, John R.  
CLMN Number of Claims: 10  
ECL Exemplary Claim: 10  
DRWN No Drawings  
LN.CNT 755


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There are described stable fluorescent labels comprising a complex of lanthanide metal and a chelating agent comprising a nucleus which is a triplet sensitizer having a triplet energy greater than that of said lanthanide metal and at least two heteroatom-containing groups which form coordinate complexes with lanthanide metals and a third heteroatom-containing group or heteroatom in or appended to the triplet sensitizer. Labeled physiologically active materials useful in specific binding assays such as labeled antigens, heptens, antibodies, hormones and the like comprising the stable fluorescent labels having physiologically active materials adsorbed or bonded thereto are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 85929-38-0P  
(preparation and hydrolysis of)  
RN 85929-38-0 USPATFULL  
CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



I

OH

IT 85916 4P  
 (; aration of)  
 RN 8591: -4 USPATFULL  
 CN Benz: propanoic acid,  $\alpha$ -[3-[3,5-bis[...bis(carboxymethyl)amino]methyl  
 ]-4-droxybenzoyl]phenyl]-4-[4-hydroxy-3,5-diiodophenoxy]-3,5-diiodo-,  
 $\alpha$ -r yl ester (9CI) (CA INDEX NAME



L13 ANSWER 14 OF 15 USPATFULL on STN  
 AN 87:4-68 USPATFULL  
 TI Fluorescent labels for immunoassay  
 IN Hinsaw, Jerald C., Ogden, UT, United States  
 Toner, John L., Webster, NY, United States  
 Reynolds, George A., Rochester, NY, United States  
 PA Eastman Kodak Company, Rochester, NY, United States (U.S. corporation)  
 PI US 4637988 19870120  
 AI US 1986-825693 19860203 (6)  
 RLI Continuation of Ser. No. US 1981-279398, filed on 1 Jul 1981, now  
 abandoned  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Schwartz, Richard A.  
 LREP Rosenstein, Arthur H.  
 CLMN Number of Claims: 30  
 ECL Exemplary Claim: 28  
 DRWN No Drawings  
 LN.CNT 972  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB There are described stable fluorescent labels comprising a complex of  
 lanthanide metal and a chelating agent comprising a nucleus which is a  
 triplet sensitizer having a triplet energy greater than that of said  
 lanthanide metal and at least two heteroatom-containing groups which

CAS ONLINE PRINTOUT

form coordinate complexes with lanthanide metals and a third heteroatom-containing group or heteroatom in or appended to the triplet sensitizer. Labeled physiologically active materials useful in specific binding assays such as labeled antigens, heptens, antibodies, hormones and the like comprising the stable fluorescent labels having physiologically active materials adsorbed or bonded thereto are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 85929-38-0P

(preparation and hydrolysis of)

RN 85929-38-0 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[4-(acetyloxy)-3,5-bis[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]benzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

/ I


/ OH

IT 85916-19-4P

(preparation of)

RN 85916-19-4 USPATFULL

CN Benzenepropanoic acid,  $\alpha$ -[3-[3,5-bis[[bis(carboxymethyl)amino]methyl]-4-hydroxybenzoyl]phenyl]-4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodo-,  $\alpha$ -methyl ester (9CI) (CA INDEX NAME)



LL13 ANSWER 15 OF 15 : ATFULL on STN

AN 5:37832 USPATF

TI Polymerization of ethylenically unsaturated monomers with  
1,1,2,2-tetracarboalkoxy-diaryl-ethane

IN de Jongh, Hendrik A. P., Oss, Netherlands

DE Jonge, Cornelis R. H. I., De Steeg, Netherlands

PA Akzo N.V., Arnhem, Netherlands (non-U.S. corporation)

PI US 3896099 19750722

AI US 1973-401604 19730928 (5)

RLI Continuation-in-part of Ser. No. US 1971-159949, filed on 1 Jul 1971,  
now abandoned

PRAI NL 1970-9925 19700703

DT Utility

FS Granted

EXNAM Primary Examiner: Schofer, Joseph L.; Assistant Examiner: Michl, Paul R.

LREP Stevens, Davis, Voller & Mosher

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 265

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A process for the free radical-initiated polymerization of ethylenically  
unsaturated monomers in the presence of a free radical initiator  
compound comprising a 1,1,2,2-tetracarboalkoxy-diaryl-ethane.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 34404-72-3

(catalysts, for polymerization of styrene)

RN 34404-72-3 USPATFULL

CN 1,1,2,2-Ethanetetracarboxylic acid, 1,2-bis(4-methylphenyl)-, tetramethyl  
ester (9CI) (CA INDEX NAME)



CAS ONLINE PRINTOUT

=>

=>

Executing the logoff script...

=> LOG H

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	98.27	711.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-28.86

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:22:38 ON 01 SEP 2007